Samsung Biologics looks to raise nearly $2.2B to fund next-phase expansion
The CDMO plans to allocate most of offering proceeds toward its PolyPeptide Group acquisition, with the remaining funds slated for Bio Campus II investment.
Read the full article on the original site.
Read Full Article